Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05894343 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Long-term Follow-up of Glutamic Acid Decarboxylase (GAD) Gene Transfer in Parkinson's Disease

StatusActive, Not Recruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Re-verified, no change to tracked fieldsv5
  2. Trial status: Enrolling by Invitation to Active, Not Recruiting
    • Enrollment target: estimated 14 to confirmed 13
    v4
  3. Re-verified, no change to tracked fieldsv3
  4. Primary and study completion dates: May 2028 to Oct 2029
    • Study sites: 5 to 6
    v2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The objective of this study is to evaluate the long-term safety of AAV-GAD delivered bilaterally to the subthalamic nuclei (STN) in participants with Parkinson's disease.
Trial Details
NCT Number NCT05894343
Lead Sponsor MeiraGTx, LLC
Conditions
(from sponsor)		 Parkinson's Disease
Related terms Parkinson Disease
Enrollment 13 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov